Abstract
Summary: Dihydrolipoamide dehydrogenase (E3) deficiency with a clinical phenotype and genotype (Gly194Cys homozygous), previously identified only in Ashkenazi Jewish patients, was diagnosed in two Palestinian Arab siblings and two unrelated Ashkenazi Jewish patients. While three of the four patients died in childhood without specific treatment, the surviving patient at age 18 years may have benefited from long-term daily supplementation with a cocktail of riboflavin, biotin, coenzyme Q and carnitine.
REFERENCES
Hong YS, Kerr DS, Craigen WJ, et al (1996) Identification of two mutations in a compound heterozygous child with dihydrolipoamide dehydrogenase deficiency. Hum Mol Genet 5: 1925 1930.
Shaag A, Saada A, Berger I, et al (1999) Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. Am J Med Genet 82: 177 182.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hong, Y.S., Korman, S.H., Lee, J. et al. Identification of a common mutation (Gly194Cys) in both Arab Moslem and Ashkenazi Jewish patients with dihydrolipoamide dehydrogenase (E3) deficiency: Possible beneficial effect of vitamin therapy. J Inherit Metab Dis 26, 816–818 (2003). https://doi.org/10.1023/B:BOLI.0000010004.12053.5b
Issue Date:
DOI: https://doi.org/10.1023/B:BOLI.0000010004.12053.5b